Anal cancer screening in low-income and middle-income countries

Blair, Kevin J.; Valderrama-Beltrán, Sandra; Bautista‐Arredondo, Sergio; Juillard, Catherine; Lombana, Luis Jorge

doi:10.1016/s2468-1253(21)00180-1

Cited by 1 publication

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A better understanding of the levels of concern among SGM for anal cancer in SSA is important to assess future uptake of screening and treatment if it were to become available. 21…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Brief Report: Prevalence and Predictors of Concern About Anal Cancer Among Sexual and Gender Minorites Living With HIV in Abuja, Nigeria

Chama

Adebiyi

Volpi

et al. 2023

JAIDS Journal of Acquired Immune Deficiency Syndromes

View full text Add to dashboard Cite

Background: Anal cancer rates are rising among sexual and gender minorities (SGM) who live with HIV and engage in anal sex. Given that secondary cancer prevention programs for nonanal cancers are underutilized in sub-Saharan Africa, our objective was to assess concerns for anal cancer and hesitancy with cancer prevention among at-risk Nigerian SGM.Methods: Within 4 weeks, SGM living with HIV were surveyed on levels of worry and hesitancy in engaging with a future anal cancer screening and treatment study. Worry was measured on a 5-point Likert scale (0%, 25%, 50%, 75%, 100%) and categorized as low #25%, moderate 50%, and high $75%. Ordinal logistic regression identified factors associated with worry by estimating unadjusted and adjusted odds ratios (aOR) and 95% confidence intervals (95% CI).Results: Of 800 enrolled SGM, median age was 32 (interquartile range: 25-38) years, 99.2% were on antiretroviral therapy, of which 78.5% reported $95% pill adherence. The prevalence of moderate and high worry was 46.9% and 39.5%, respectively. Increasing worry was associated with reporting as a bottom for sexual position (aOR: 3.12; 95% CI: 2.04 to 4.80), top or bottom for sexual position (aOR: 2.94; 95% CI: 1.92 to 4.52), or knowing anyone with anal cancer (aOR: 2.99; 95% CI: 1.36 to 6.57). Participants aged $35 years were less worried (aOR: 0.72; 95% CI: 0.59 to 0.95). Ninetynine percent of participants provided contact information for a future cancer prevention study.Discussion: SGM who heard about and engaged in at-risk practices for anal cancer were willing to access secondary prevention. Addressing biopsychosocial factors such as age could foster future engagement.

show abstract

“…A better understanding of the levels of concern among SGM for anal cancer in SSA is important to assess future uptake of screening and treatment if it were to become available. 21…”

Section: Introductionmentioning

confidence: 99%

“…A better understanding of the levels of concern among SGM for anal cancer in SSA is important to assess future uptake of screening and treatment if it were to become available. 21 Recently, a randomized controlled trial in the United States. found screening and treating anal precancerous lesions was efficacious at preventing anal cancer.…”

Section: Introductionmentioning

confidence: 99%